NCT00022945View on ClinicalTrials.gov

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

Not specified

Conditions

Mantle Cell Lymphoma

Interventions

DRUG

Iodine-131 Anti-B1 Antibody

DRUG

Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)

Trial Locations (3)

10021

Memorial Sloan-Kettering Cancer Center, New York

19104

Hospital of the University of Pennsylvania, Philadelphia

60612

Rush-Presbyterian-St. Lukes Medical Center, Chicago

Sponsors

Lead Sponsor

Corixa Corporation

All Listed Sponsors

lead

Corixa Corporation

INDUSTRY

NCT00022945 - Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter